These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 9037203

  • 1. Defining the minimal structural requirements for partial agonism at the type I myo-inositol 1,4,5-trisphosphate receptor.
    Wilcox RA, Fauq A, Kozikowski AP, Nahorski SR.
    FEBS Lett; 1997 Feb 03; 402(2-3):241-5. PubMed ID: 9037203
    [Abstract] [Full Text] [Related]

  • 2. 2-Hydroxyethyl-alpha-D-glucopyranoside-2,3',4'-trisphosphate, a novel, metabolically resistant, adenophostin A and myo-inositol-1,4,5-trisphosphate analogue, potently interacts with the myo-inositol-1,4,5-trisphosphate receptor.
    Wilcox RA, Erneux C, Primrose WU, Gigg R, Nahorski SR.
    Mol Pharmacol; 1995 Jun 03; 47(6):1204-11. PubMed ID: 7603461
    [Abstract] [Full Text] [Related]

  • 3. Molecular recognition at the myo-inositol 1,4,5-trisphosphate receptor. 3-position substituted myo-inositol 1,4,5-trisphosphate analogues reveal the binding and Ca2+ release requirements for high affinity interaction with the myo-inositol 1,4,5-trisphosphate receptor.
    Wilcox RA, Challiss RA, Traynor JR, Fauq AH, Ognayanov VI, Kozikowski AP, Nahorski SR.
    J Biol Chem; 1994 Oct 28; 269(43):26815-21. PubMed ID: 7929418
    [Abstract] [Full Text] [Related]

  • 4. Myo-inositol 1,3,4,5-tetrakisphosphate can independently mobilise intracellular calcium, via the inositol 1,4,5-trisphosphate receptor: studies with myo-inositol 1,4,5-trisphosphate-3-phosphorothioate and myo-inositol hexakisphosphate.
    Wilcox RA, Whitham EM, Liu C, Potter BV, Nahorski SR.
    FEBS Lett; 1993 Dec 27; 336(2):267-71. PubMed ID: 8262243
    [Abstract] [Full Text] [Related]

  • 5. Modification at C2 of myo-inositol 1,4,5-trisphosphate produces inositol trisphosphates and tetrakisphosphates with potent biological activities.
    Wilcox RA, Safrany ST, Lampe D, Mills SJ, Nahorski SR, Potter BV.
    Eur J Biochem; 1994 Jul 01; 223(1):115-24. PubMed ID: 8033885
    [Abstract] [Full Text] [Related]

  • 6. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
    Murphy CT, Bullock AJ, Lindley CJ, Mills SJ, Riley AM, Potter BV, Westwick J.
    Mol Pharmacol; 1996 Nov 01; 50(5):1223-30. PubMed ID: 8913354
    [Abstract] [Full Text] [Related]

  • 7. Interaction of synthetic D-6-deoxy-myo-inositol 1,4,5-trisphosphate with the Ca2(+)-releasing D-myo-inositol 1,4,5-trisphosphate receptor, and the metabolic enzymes 5-phosphatase and 3-kinase.
    Safrany ST, Wojcikiewicz RJ, Strupish J, Nahorski SR, Dubreuil D, Cleophax J, Gero SD, Potter BV.
    FEBS Lett; 1991 Jan 28; 278(2):252-6. PubMed ID: 1846823
    [Abstract] [Full Text] [Related]

  • 8. The novel Ins(1,4,5)P3 analogue 3-amino-3-deoxy-Ins(1,4,5)P3: a pH-dependent Ins(1,4,5)P3 receptor partial agonist in SH-SY5Y neuroblastoma cells.
    Kozikowski AP, Fauq AH, Wilcox RA, Challiss RA, Nahorski SR.
    J Med Chem; 1994 Mar 18; 37(6):868-72. PubMed ID: 8145238
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and application of photoaffinity analogues of inositol 1,4,5-trisphosphate selectively substituted at the 1-phosphate group.
    Schäfer R, Nehls-Sahabandu M, Grabowsky B, Dehlinger-Kremer M, Schulz I, Mayr GW.
    Biochem J; 1990 Dec 15; 272(3):817-25. PubMed ID: 2176480
    [Abstract] [Full Text] [Related]

  • 10. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells.
    Wilcox RA, Challiss RA, Liu C, Potter BV, Nahorski SR.
    Mol Pharmacol; 1993 Oct 15; 44(4):810-7. PubMed ID: 8232232
    [Abstract] [Full Text] [Related]

  • 11. Identification of partial agonists with low intrinsic activity at the inositol-1,4,5-trisphosphate receptor.
    Safrany ST, Wilcox RA, Liu C, Dubreuil D, Potter BV, Nahorski SR.
    Mol Pharmacol; 1993 Apr 15; 43(4):499-503. PubMed ID: 8386304
    [Abstract] [Full Text] [Related]

  • 12. Ca2(+)-mobilising properties of synthetic fluoro-analogues of myo-inositol 1,4,5-trisphosphate and their interaction with myo-inositol 1,4,5-trisphosphate 3-kinase and 5-phosphatase.
    Safrany ST, Sawyer D, Wojcikiewicz RJ, Nahorski SR, Potter BV.
    FEBS Lett; 1990 Dec 10; 276(1-2):91-4. PubMed ID: 2176165
    [Abstract] [Full Text] [Related]

  • 13. 3-position modification of myo-inositol 1,4,5-trisphosphate: consequences for intracellular Ca2+ mobilisation and enzyme recognition.
    Safrany ST, Wilcox RA, Liu C, Potter BV, Nahorski SR.
    Eur J Pharmacol; 1992 Jul 01; 226(3):265-72. PubMed ID: 1330634
    [Abstract] [Full Text] [Related]

  • 14. Structural analogues of D-myo-inositol-1,4,5-trisphosphate and adenophostin A: recognition by cerebellar and platelet inositol-1,4,5-trisphosphate receptors.
    Murphy CT, Riley AM, Lindley CJ, Jenkins DJ, Westwick J, Potter BV.
    Mol Pharmacol; 1997 Oct 01; 52(4):741-8. PubMed ID: 9380038
    [Abstract] [Full Text] [Related]

  • 15. Synthetic D- and L-enantiomers of 2,2-difluoro-2-deoxy-myo-inositol 1,4,5-trisphosphate interact differently with myo-inositol 1,4,5-trisphosphate binding proteins: identification of a potent small molecule 3-kinase inhibitor.
    Safrany ST, Sawyer DA, Nahorski SR, Potter BV.
    Chirality; 1992 Oct 01; 4(7):415-22. PubMed ID: 1334423
    [Abstract] [Full Text] [Related]

  • 16. Molecular interactions of endogenous D-myo-inositol phosphates with the intracellular D-myo-inositol 1,4,5-trisphosphate recognition site.
    Lu PJ, Gou DM, Shieh WR, Chen CS.
    Biochemistry; 1994 Sep 27; 33(38):11586-97. PubMed ID: 7918372
    [Abstract] [Full Text] [Related]

  • 17. Disaccharide polyphosphates based upon adenophostin A activate hepatic D-myo-inositol 1,4,5-trisphosphate receptors.
    Marchant JS, Beecroft MD, Riley AM, Jenkins DJ, Marwood RD, Taylor CW, Potter BV.
    Biochemistry; 1997 Oct 21; 36(42):12780-90. PubMed ID: 9335535
    [Abstract] [Full Text] [Related]

  • 18. myo-inositol 1,4,6-trisphosphorothioate and myo-inositol 1,3, 6-trisphosphorothioate: partial agonists with very low intrinsic activity at the platelet myo-inositol 1,4,5-trisphosphate receptor.
    Murphy CT, Riley AM, Mills SJ, Lindley CJ, Potter BV, Westwick J.
    Mol Pharmacol; 2000 Mar 21; 57(3):595-601. PubMed ID: 10692501
    [Abstract] [Full Text] [Related]

  • 19. Acyclophostin: a ribose-modified analog of adenophostin A with high affinity for inositol 1,4,5-trisphosphate receptors and pH-dependent efficacy.
    Beecroft MD, Marchant JS, Riley AM, Van Straten NC, Van der Marel GA, Van Boom JH, Potter BV, Taylor CW.
    Mol Pharmacol; 1999 Jan 21; 55(1):109-17. PubMed ID: 9882704
    [Abstract] [Full Text] [Related]

  • 20. Synthetic phosphorothioate-containing analogues of inositol 1,4,5-trisphosphate mobilize intracellular Ca2+ stores and interact differentially with inositol 1,4,5-trisphosphate 5-phosphatase and 3-kinase.
    Safrany ST, Wojcikiewicz RJ, Strupish J, McBain J, Cooke AM, Potter BV, Nahorski SR.
    Mol Pharmacol; 1991 Jun 21; 39(6):754-61. PubMed ID: 1646949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.